Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among adults. This powerful treatment features tirzepatide, which works with your ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may pose heightened risks for kidney, pancreatic, and gastrointestinal problems.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...